| ||||||||||||||||
| ||||||||||||||||
— Genentech —Top tagsYou have executed a tag search on The Deal Newsweekly. To the right you will find a comprehensive list of stories tagged "Genentech." Below are the most-popular tags for The Deal Newsweekly. On the right of the page you will find a search box to dig deeper into our content.
Community
 Entries tagged "Genentech"Bayside landingSusan Desmond-Hellmann, Genentech's former chief of product development since 2004, takes over the chancellor's chair at the University of California, San Francisco. Antitrust 2.0The return of tech dealmaking brings with it a revived threat of scrutiny. Nothing venturedWhy a revitalized venture capital industry is essential to economic recovery. Little pharma bluesAs the economy foundered, drug industry insiders looked forward to an M&A frenzy. But with a few exceptions, deals occurred only at the top of the food chain. Merck, Schering play follow the pharmaDamian Ridealgh and other Fried Frank attorneys advised Merck on its deal for Schering. The big trialFrom VC to licensing, Exelixis has done every kind of deal to keep itself afloat, except one. Is an acquisition next? Risk Arbitrage: March 9, 2009March 9, 12 and 20 are important days in the M&A world. Davis Polk, Roche probe Genentech's DNARoche and Genentech have a long history. This time around, Davis Polk's John Butler and others take the lead for Roche. Surprise!For sheer drama, Roche's hostile, discounted bid for Genentech tops even Pfizer's bid for Wyeth. Mood enhancersDrug companies get a warm reception in the debt market these days. Risk Arbitrage: Feb. 9, 20092009 has begun better than it might have on the M&A front. They need a new drugExpect Big Pharma to go shopping in biotechland, but with an eye for fire sales. Beyond fluxMarket chaos has effectively stifled most M&A activities. But investment bankers already look ahead to when a kind of dealmaking normalcy prevails. Risk Arb updateUncertainty in banking and M&A credit markets have hammered share prices of targets of hostile bids, along with the broader stock market. Risk arbitrageGenentech management hits the road, while a special committee discusses a deal with Roche, and Teck-Fording gauges Canadian pension funds' interest in Fording units ahead of the deal's close. The end of a long and beautiful friendshipRoche has let Genentech flourish -- at arm's length. Now, if a buyout gets done, that could change. | ||||||||||||||||
|
|
|
|
|
